Fluorouracil Solution
NDC Package 51672-4063-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Fluorouracil solution is fluorouracil is used to treat various types of cancer. This formulation utilizes a solution delivery system. Marketed by Taro Pharmaceuticals U.s.a., Inc., this product is identified by NDC 51672-4063 and is authorized under FDA application ANDA076526.

Identification & Billing

NDC Package Code
51672-4063-1
Package Description
1 BOTTLE in 1 CARTON / 10 mL in 1 BOTTLE
Product Code
51672-4063
11-Digit Billing Format
51672406301
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Fluorouracil
Non-Proprietary Name
Fluorouracil
Substance Name
Fluorouracil
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
FLUOROURACIL 50 mg/mL
Pharmacologic Class
Usage Information
Fluorouracil is used to treat various types of cancer. It is a chemotherapy drug that is used to slow or stop cancer cell growth. You should be tested for a DPD enzyme deficiency before you start treatment with fluorouracil. Ask your doctor for more details.

Regulatory & Marketing

Labeler Name
Taro Pharmaceuticals U.s.a., Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA076526
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-05-2003
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51672-4063-1 identifies a specific commercial package of 1 bottle in 1 carton / 10 ml in 1 bottle of Fluorouracil, a human prescription drug labeled by Taro Pharmaceuticals U.s.a., Inc.. This solution is formulated for topical use and contains fluorouracil as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Taro Pharmaceuticals U.s.a., Inc. on November 05, 2003. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Fluorouracil is used to treat various types of cancer. It is a chemotherapy drug that is used to slow or stop cancer cell growth. You should be tested for a DPD enzyme deficiency before you start treatment with fluorouracil. Ask your doctor for more details.

How is this Taro Pharmaceuticals U.s.a., Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51672406301. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51672-4063-1
11-Digit CMS (5-4-2)
51672-4063-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.